iRegene’s NouvSight001 Cleared for Retinitis Pigmentosa Trials in China and U.S.
iRegene Therapeutics has secured regulatory clearance in both China and the United States to move NouvSight001, its off-the-shelf photoreceptor cell therapy, into clinical development for retinitis pigmentosa (RP), giving the company another opportunity…
Hengrui Advances SHR-8203 Into Phase 1/2 Study in Advanced Solid Tumors, With Filing Hinting at Potential PD-1/VEGF/CTLA-4 Trispecific
Chinese pharmaceutical giant Hengrui Pharma has registered a new clinical study of SHR-8203 injection on China’s drug trial registration platform, moving the previously undisclosed biologic into a multicenter Phase 1/2 trial in patients with…